RayJay on Veeva (VEEV): 'we haven’t heard any official designation on Bristol-Myers Squib’s plans for CRM going forward, our understanding is that CRM add-ons won’t be portable to Salesforce'
Tweet Send to a Friend
Raymond James analyst Brian Peterson reiterated an Outperform rating and $285.00 price target on Veeva Systems (NYSE: VEEV)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
